789 related articles for article (PubMed ID: 25538263)
1. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
3. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
6. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
7. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
17. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
[TBL] [Abstract][Full Text] [Related]
18. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
19. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]